This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Zaorsky NG , Sun YG , Wang ZX , Palmer J , Fortina PM , Solomides C , Werner-Wasik M , Dicker AP , Axelrod R , Campling B , Evans N , Cowan S , Lu B
Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab
Cancer Biology & Therapy. 2013 Oct;14(10) :883-887
PMID: WOS:000327420700008 PMCID: PMC 3926884
AbstractRTOG 0839 is a Phase II study of pre-operative chemoradiotherapy with or without panitumumab in potentially operable locally advanced non-small cell lung cancer (NSCLC). The investigational agent, panitumumab, is an anti-epithelial growth factor receptor (EGFR) antibody that improves progression-free survival in chemorefractory metastatic colorectal cancer (mCRC). Recently, both KRAS mutational status (i.e., mutated or not) and subtype (i.e., activating or inactivating) have been shown to be predictive of response to anti-EGFR therapy in mCRC. However, in NSCLC, it is unknown if KRAS mutational status or subtype predict benefit to anti-EGFR therapies because of unique genetic and epigenetic factors unique to each cancer. We present a patient with stage III NSCLC containing a KRAS G12D activating mutation who had a partial pathologic response, with disappearance of a minor KRAS mutant clone. This case suggests possible eradication of the G12D KRAS lung cancer clones by concurrent chemoradiation with panitumumab.
NotesZaorsky, Nicholas G. Sun, Yunguang Wang, Zixuan Palmer, Joshua Fortina, Paolo M. Solomides, Charalambos Werner-Wasik, Maria Dicker, Adam P. Axelrod, Rita Campling, Barbara Evans, Nathaniel, III Cowan, Scott Lu, Bo